Cencora, Inc. (COR)

In the past six months, Cencora's stock has seen several notable events and trends. The stock price has increased by 32.90% between June 28, 2024, and June 27, 2025, and has risen by 32.77% over the past six months. Cencora reported strong results for Q1 and Q2 Fiscal 2025, leading to raised full-year guidance. The company declared quarterly cash dividends and has been actively repurchasing shares, including an agreement to repurchase approximately $400 million of its common stock from Walgreens Boots Alliance Holdings LLC. Walgreens Boots Alliance has continued to sell shares in Cencora, reducing its stake to about 6% in February 2025. Analysts have a predominantly positive outlook on the stock.

Cencora's demand for products and services is generally resilient, but some seasonality can be observed. Demand for vaccines, including flu vaccines, can experience higher-than-expected seasonal trends. Demand for global specialty logistics services related to clinical trial activity can be subdued at times. Cencora's business model benefits from increased drug utilization and the adoption of generics and biosimilars, with anticipated growth in prescription utilization trends.

Cencora, Inc., formerly known as AmerisourceBergen Corporation, is a global pharmaceutical sourcing and distribution services company headquartered in Conshohocken, Pennsylvania. The company plays a crucial role in the global healthcare supply chain, aiming to reduce healthcare costs and improve patient outcomes. Cencora operates primarily within the pharmaceutical distribution sector and the broader healthcare industry. It is considered one of the largest pharmaceutical companies globally and, alongside McKesson and Cardinal Health, constitutes over 90% of the U.S. pharmaceutical wholesale industry. Cencora operates through two main segments: U.S. Healthcare Solutions and International Healthcare Solutions. Major products and services include pharmaceutical distribution, specialty pharmaceutical services, global sourcing and manufacturer relationships, global specialty logistics, animal health, pharmacy management and consulting services, data analytics and outcomes research, and clinical trial support.

Cencora has a significant global footprint, with its headquarters in Conshohocken, Pennsylvania, and numerous regional offices and distribution centers across the globe. Its operations extend across various global business segments, including International Healthcare Solutions, which focuses on international pharmaceutical wholesale and related service operations, primarily in Europe and Canada. The acquisition of Alliance Healthcare in 2021 expanded its international presence, and Cencora conducts operations in over 50 countries.

Cencora's brand reputation has been shaped by its rebranding from AmerisourceBergen, its involvement in opioid litigation, a decline in net income in Q1 Fiscal 2025, goodwill impairment related to PharmaLex, positive analyst sentiment, and strategic acquisitions and partnerships. The rebranding aimed to unify employees and underscore its commitment to connecting manufacturers, providers, pharmacies, and patients. Opioid-related lawsuits and declining net income due to increased operating expenses pose reputational risks. Positive analyst sentiment and strategic acquisitions contribute positively to its reputation.

Cencora, Inc. has a mixed ownership structure, including institutional, insider, and retail investors. There are a large number of institutional owners and shareholders, with major holders including Vanguard Group Inc., BlackRock, Inc., and Price T Rowe Associates Inc. Walgreens Boots Alliance Inc. is highlighted as the largest individual Cencora shareholder, and insiders hold approximately 6.79% of the company's stock.